SCHEMBL16631725

SCHEMBL16631725

Cc1ccc(F)nc1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HCAR2 Q8TDS4 1/20 0.38
KMO O15229 2/20 0.37
KDM4E B2RXH2 3/20 0.37
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37
PIN1 Q13526 1/20 0.37
RBP4 P02753 1/20 0.36
MEN1 O00255 1/20 0.36
GLA P06280 1/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MCL1 Q07820 1/20 0.34
HSD17B10 Q99714 2/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38658343 0.79 CTSA (0.40) CTSAALDH1A1SMN1; SMN2PIN1KMT2A
SCHEMBL16631730 0.79 NPSR1 (0.48) CTSAALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL3792291 0.78 ALDH1A1 (0.41) CTSAALDH1A1MAPTSMN1; SMN2KMO
SCHEMBL2373944 0.78 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2KDM4EPIN1
SCHEMBL31645569 0.78 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2KDM4EASPH
SCHEMBL2222443 0.77 ALDH1A1 (0.40) ALDH1A1MAPTSMN1; SMN2KDM4EPIN1
SCHEMBL8666506 0.77 KDM4E (0.47) ALDH1A1MAPTSMN1; SMN2KDM4EASPH
SCHEMBL19857471 0.77 KDM4E (0.48) ALDH1A1MAPTSMN1; SMN2KDM4EPIN1
SCHEMBL21332489 0.75 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2KDM4EPIN1
SCHEMBL20475332 0.75 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2KDM4EPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
EP-4667467-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2025-12-24 EP disclosed
WO-2023078401-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-11 WO disclosed
EP-3668871-B1 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-08-04 EP disclosed
US-10913741-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2021-02-09 US disclosed
US-20200392137-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR BRISTOL-MYERS SQUIBB COMPANY 2020-12-17 US disclosed
US-10793569-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2020-10-06 US disclosed
US-20200255429-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR BRISTOL-MYERS SQUIBB COMPANY 2020-08-13 US disclosed
EP-3668871-A1 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS Bristol-Myers Squibb Company (US) 2020-06-24 EP disclosed
US-10689382-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-23 US disclosed
US-20200095248-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR BRISTOL-MYERS SQUIBB COMPANY 2020-03-26 US disclosed
US-10508115-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2019-12-17 US disclosed
WO-2019035971-A1 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-21 WO disclosed
US-20190055247-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR BRISTOL-MYERS SQUIBB COMPANY 2019-02-21 US disclosed
EP-3083586-B1 NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS Bayer Pharma AG (DE) 2018-04-18 EP disclosed
EP-3083586-A1 NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015091426-A1 NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 CTSA 4234/4885ALDH1A1 4189/4885MAPT 3290/4885
US-10508115-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-20200255429-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-10793569-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-10913741-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor TLR7, TLR1, TLR8 CTSA 1579/4885ALDH1A1 2345/4885MAPT 3095/4885
US-20200095248-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-20190055247-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-20200392137-A1 TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885
US-10689382-B2 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor TLR7, TLR1, TLR8 CTSA 1594/4885ALDH1A1 2375/4885MAPT 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.